Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 18/20 | 0.54 |
| ▸ | ATP4B | P51164 | 18/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaltidine SCHEMBL635743 | 0.99 | ATP4A (0.53) | ATP4AATP4BMAPTNPC1RAB9A | |
| Zaltidine SCHEMBL4606700 | 0.74 | ATP4A (0.63) | ATP4AATP4BMAPTNPC1RAB9A | |
| Zaltidine SCHEMBL10367794 | 0.72 | ATP4A (0.41) | ATP4AATP4B | |
| SCHEMBL6985595 | 0.69 | MAPT (0.57) | ATP4AATP4BMAPTNPC1RAB9A | |
| Bromide SCHEMBL826907 | 0.69 | MAPT (0.97) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL11021937 | 0.69 | ATP4A (0.54) | ATP4AATP4BMAPTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6989280 | 0.68 | MAPT (0.56) | ATP4AATP4BMAPTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9292234 | 0.67 | ATP4A (0.54) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL823907 | 0.66 | ATP4A (1.00) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL9298276 | 0.66 | ATP4A (0.57) | ATP4AATP4BMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | claimed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | claimed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | claimed |
| WO-2019150388-A1 | NOVEL GLUCOSE OXIDASE COMPOSITIONS | Veganutritech LLP (IN) | 2019-08-08 | — | — | WO | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | claimed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| CN-101607086-B | Compound bismuth composition and preparation method thereof | SHANXI ANTE BIO PHARMACEUTICAL CO LTD | 2011-11-02 | — | — | CN | claimed |
| CN-101607086-A | A kind of compound bismuth composition and preparation method thereof | SHANXI ANTE BIO PHARMACEUTICAL (CN) | 2009-12-23 | — | — | CN | claimed |
| CN-101584681-A | Tablet capsule for treating helicobacter pylori infection | HEILONGJIANG FUHE HUAXING PHAR (CN) | 2009-11-25 | — | — | CN | claimed |
| WO-1996016640-A1 | ORAL COMPOSITIONS OF H2-ANTAGONISTS | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1996-06-06 | — | — | WO | claimed |
| US-5503846-A | Base coated acid particles and effervescent formulation incorporating same | CIMA LABS, INC. (US) | 1996-04-02 | — | — | US | claimed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| WO-1994021239-A1 | EFFERVESCENT FORMULATIONS OF BASE COATED ACID PARTICLES | CIMA LABS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | claimed |
| EP-0367484-B1 | Carboxylic acid derivates | GLAXO GROUP LTD (GB) | 1994-02-16 | — | — | EP | claimed |
| US-5273984-A | Bismuth complex having a carboxylic acid to form a salt of the basic antagonist excluding ranitidine | GLAXO GROUP LIMITED (GB) | 1993-12-28 | — | — | US | claimed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0454449-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | claimed |
| EP-0367484-A1 | Carboxylic acid derivates | GLAXO GROUP LIMITED (GB) | 1990-05-09 | — | — | EP | claimed |